Actively Recruiting
Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
Led by Novartis Pharmaceuticals · Updated on 2026-06-08
395
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of Jakavi4 (ruxolitinib) in patients who have acute or chronic graft-versus-host disease (GVHD) during routine clinical practice. This observational study is sponsored by Novartis Pharmaceuticals and focuses on understanding how ruxolitinib works in real-world settings to help patients with GVHD. Patients with acute and chronic GVHD who are treated with ruxolitinib are followed as part of this study. There is one study group consisting of patients receiving ruxolitinib. The study monitors patients over time to gather data on infections, deaths related to infection, and other health events up to one year after treatment. Participants will have their health closely monitored throughout the study period, including the number and severity of infections, response to treatment for GVHD, survival, and bone-related events. Data on overall response rates for acute and chronic GVHD, timing of responses, and duration of effects will also be collected. The study lasts up to one year for each participant, during which researchers review medical records and outcomes related to their GVHD and treatment with ruxolitinib.
CONDITIONS
Brief Title
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute and chronic GVHD
- Patients treated with ruxolitinib
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants who have acute or chronic GVHD treated with ruxolitinib are observed for safety and outcomes.
Trial Site Locations
Total: 1 location
1
Novartis
Tokyo, Japan, 105-6333
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here